|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Brent Del Monte |
Date | 4/20/2015 5:58:05 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Genetically Engineered (GE) Animals
-FDA Approval
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Amendment to Restrict FDA Approval of GE Salmon
--Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
-H.R. 1599: Safe and Accurate Food Labeling Act of 2015
-U.S. Government Policy
Funding for the USDA
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Foreign Agricultural Biotechnology Laws and Regulations
-China Biotechnology Regulations
-Asynchrony of International Approvals
-EU Ag-Biotech Policies and Regulations
Potential Regulation of New Genetic Modification Technologies
Funding for Biomass Crop Assistance Program
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Transatlantic Trade and Investment Partnership
-Ag-Biotech Issues
USDA/APHIS Agricultural Biotechnology Regulations
-Coexistence of Production Systems
-Efficient Science-Based Review of Biotech Products
Trade Promotion Authority
Local GE Crop Cultivation Bans
Coordination of Federal Biotechnology Research
-H.R. 591: Engineering Biology Research and Development Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Cathleen |
Enright |
|
|
|
Dana |
OBrien |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
-FDA Approval
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for the USDA
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for FDA
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-S 320: Medical Innovation Act of 2015
Funding for Centers for Disease Control and Prevention Vaccine Programs
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for National Institutes of Health
-S 320: Medical Innovation Act of 2015
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Biomass Crop Assistance Program
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Sequestration of PDUFA Fees
-H.R. 1078: FDA Safety over Sequestration Act
Funding for Biofuels
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-Department of Defense Appropriations Act for FY 2016
-Department of Defense Funding of Advanced Biofuels
-Energy and Water Development and Related Agencies Appropriations Act for FY 2016
Senate Budget Resolution S. Con. Res. 11
- Amendment on Medicare non-interference provision
- Amendment on compounded drugs across state lines
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
- Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Erick |
Lutt |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Tom |
DiLenge |
|
|
|
Jeffrey |
Peters |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
-H.R. 9: Innovation Act
-Targeting Rogue and Opaque Letters (TROL) Act of 2015 (Discussion Draft)
-Implementation of the America Invents Act of 2011
-S. 632: STRONG Patents Act
Inter Partes Review
- S. 632: STRONG Patents Act
- Implementation of the America Invents Act of 2011
World Trade Organization Special 301 Submissions
IP Rights for Environmental Technologies
- U.S. Government Position for U.N. Convention on Climate Change Negotiations
TransPacific Partnership
-Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
-Intellectual Property Issues
Patenting of Biological Inventions
-PTO Examination Guidelines
Trade Promotion Authority
Colombia National Development Plan
-Intellectual Property Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Charles |
Fritts |
|
|
|
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Jamie |
Gregorian |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Genetically Engineered (GE) Animals
-FDA Approval
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
Review and Labeling of Food Derived From Biotechnology
-H.R. 1599: Safe and Accurate Food Labeling Act of 2015
-U.S. Government Policy
Drug Evaluation and Review
-Compassionate Use/Expanded Access
-Implementation of the FDA Safety and Innovation Act
Biosimilars
-Biosimilar User Fee Act Implementation
-Colombia Biologics Regulations
-Implementation of Affordable Care Act
-Interchangeability and Pharmacy Substitution
-Mexico Biologics Regulations
-Naming
-Patent Certification
USDA/APHIS Agricultural Biotechnology Regulations
-Coexistence of Production Systems
-Efficient Science-Based Review of Biotech Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Cathleen |
Enright |
|
|
|
Dana |
OBrien |
|
|
|
Kathleen |
Holcombe |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Jeffrey |
Peters |
|
|
|
Matthew |
O'Mara |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
-Department of Defense Application of Advanced Biofuels
-Implementation of the Agricultural Act of 2014
-Production Tax Credit Extension
-Renewable Fuel Standard
Renewable Chemicals/Bio-based Products (Non-Funding)
-New Production Tax Credit
-Expansion of Master Limited Partnerships to Renewable Chemicals
Funding for Renewable Chemicals/Bio-based Products
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biomass Crop Assistance Program
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biofuels
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-Department of Defense Appropriations Act for FY 2016
-Department of Defense Funding of Advanced Biofuels
-Energy and Water Development and Related Agencies Appropriations Act for FY 2016
EPA Regulation of Biotechnology
-Interior, Environment, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Treasury - Dept of, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Tracey |
LaTurner |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
-FDA Approval
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Amendment on GE Salmon Labeling
--Amendment to Restrict FDA Approval of GE Salmon
Review and Labeling of Food Derived From Biotechnology
-H.R. 1599: Safe and Accurate Food Labeling Act of 2015
-U.S. Government Policy
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Dana |
OBrien |
|
|
|
Tracey |
LaTurner |
|
|
|
Cathleen |
Enright |
|
|
|
Matthew |
OMara |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
-Department of Defense Application of Advanced Biofuels
-Implementation of the Agricultural Act of 2014
-Production Tax Credit Extension
-Renewable Fuel Standard
Renewable Chemicals/Bio-based Products (Non-Funding)
-New Production Tax Credit
-Expansion of Master Limited Partnerships to Renewable Chemicals
Funding for Renewable Chemicals/Bio-based Products
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biomass Crop Assistance Program
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biofuels
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-Department of Defense Appropriations Act for FY 2016
-Department of Defense Funding of Advanced Biofuels
-Energy and Water Development and Related Agencies Appropriations Act for FY 2016
EPA Regulation of Biotechnology
-Interior, Environment, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Treasury - Dept of, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars
-Biosimilar User Fee Act Implementation
-Colombia Biologics Regulations
-Implementation of Affordable Care Act
-Interchangeability and Pharmacy Substitution
-Mexico Biologics Regulations
-Naming
-Patent Certification
Funding for National Institutes of Health
-S 320: Medical Innovation Act of 2015
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Vaccine Access/Financing
-Adult Immunization (Senate Discussion Draft)
-S.2694: Ensuring Access to Primary Care for Women and Children Act
340B Drug Pricing Program
-Implementation of Affordable Care Act
-Program Implementation & Oversight
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for FDA
-Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-S 320: Medical Innovation Act of 2015
Independent Payment Advisory Board
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Biodefense Research, Development, and Procurement Issues (Non-funding)
TransPacific Partnership
-Data and Intellectual Property Protection for Pharmaceuticals
-Regulatory Transparency
Transatlantic Trade and Investment Partnership
-Intellectual Property Issues
-Regulatory Harmonization
-Reimbursement Transparency
Reimbursement for Innovative Products
-Medicare Part D Prescription Drug Program
-Medicare Part B Physician-Administered Products
Sequestration of PDUFA Fees
--H.R. 1078: FDA Safety over Sequestration Act
Drug Evaluation and Review
-Compassionate Use/Expanded Access
-Implementation of the FDA Safety and Innovation Act
Orphan Drug Act Tax Credit
Medicare Physician Payment Sustainable Growth Rate Formula
- HR 2: Medicare Access and CHIP Reauthorization Act of 2015
21st Century Cures Initiative
-Biomarkers and Regulatory Science Improvements
-Communication with Healthcare Professionals
-Expanded Access to Investigational Drugs
-Expedited Pathways
-FDA Hiring Flexibility
-FDA Management and Financial Accountability
-Innovation Incentives
-Longitudinal Study of Chronic Diseases
-Patient Access to Approved Drugs
-Patient-Focused Drug Development
-Use of Real-World Evidence
-Vaccine and Anti-Microbial Resistance Product Development and Incentives
-ADAPT Act (House Discussion Draft)
-Sunshine Act Amendments
-Coding
-Coverage with Evidence Development
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Senate Budget Resolution S. Con. Res. 11
- Amendment on Medicare non-interference provision
- Amendment on compounded drugs across state lines
Vaccines and Infectious Diseases - General
Colombia National Development Plan
-Regulatory Issues
-Reimbursement Issues
-Intellectual Property Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Cartier |
Esham |
|
|
|
Catharine |
Harris |
|
|
|
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Derrick |
White |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeffrey |
Peters |
|
|
|
Joseph |
Damond |
|
|
|
Kathleen |
Holcombe |
|
|
|
Laurel |
Todd |
|
|
|
Phyllis |
Arthur |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Hans |
Sauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development, and Procurement Issues (Non-funding)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
-ADAPT Act (House Discussion Draft)
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
EPA Regulation of Biotechnology
-Interior, Environment, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Brent |
DelMonte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
-S 320: Medical Innovation Act of 2015
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
21st Century Cures Initiative
-Longitudinal Study of Chronic Diseases
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
-ADAPT Act (House Discussion Draft)
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
-Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Jamie |
Gregorian |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeffrey |
Peters |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Independent Payment Advisory Board
Reimbursement for Innovative Products
-Medicare Part D Prescription Drug Program
-Medicare Part B Physician-Administered Products
Medicare Physician Payment Sustainable Growth Rate Formula
-HR 2: Medicare Access and CHIP Reauthorization Act of 2015
21st Century Cures Initiative
-Patient Access to Approved Drugs
-Coding
-Coverage with Evidence Development
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Jeffrey |
Peters |
|
|
|
Laurel |
Todd |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
-Public Company Accounting Oversight Board Audit Cost Increases
Capital Formation Investment Incentives
-Reform of Capital Gains Rules
-Reform of Net Operating Loss Rules
-Reform of Passive Loss Rules
-PARTNER Act (House Discussion Draft)
-S. 341: Start-up Jobs and Innovation Act
-S. 537: COMPETE Act
Expansion of Exemption under SEC Regulation A
- Proposed Legislation
-Proposed SEC Rule on Reg A+
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
-Fostering Innovation Act (House Discussion Draft)
XBRL Exemption for Small Public Companies
-H.R. 37: Promoting Job Creation and Reducing Small Business Burdens Act
-Small Company Disclosure Simplification Act (House Discussion Draft)
Stock Exchange Tick Size
-H.R. 37: Promoting Job Creation and Reducing Small Business Burdens Act
Capital Market Enhancements
-H.R. 1525: Disclosure Modernization and Simplification Act
-H.R. 1723: Small Company Simple Registration Act
-S. 576: Encouraging Employee Ownership Act
-SEC Office of Small Business Policy Responsibilities
-Small Business Freedom to Grow Act (House Discussion Draft)
-Improving Access to Capital for Emerging Growth Companies Act (House Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Charles |
Crain |
|
|
|
Shelly Mui-Lipnik |
Mui-Lipnik |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels
-Production Tax Credit Extension
Research & Development Tax Credit Reforms
-Permanency
-Extension
-S. 537: COMPETE Act
-S. 341: Start-up Jobs and Innovation Act
Capital Formation Investment Incentives
-Reform of Capital Gains Rules
-Reform of Net Operating Loss Rules
-Reform of Passive Loss Rules
-S. 341: Start-up Jobs and Innovation Act
-S. 537: COMPETE Act
-PARTNER Act (House Discussion Draft)
Renewable Chemicals/Bio-based Products
-New Production Tax Credit
-Expansion of Master Limited Partnerships to Renewable Chemicals
Tax Reform
Orphan Drug Act Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Derrick |
White |
|
|
|
Erick |
Lutt |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Rina |
Singh |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
World Trade Organization Special 301 Submissions
Foreign Agricultural Biotechnology Laws and Regulations
-China Biotechnology Regulations
-Asynchrony of International Approvals
-EU Ag-Biotech Policies and Regulations
TransPacific Partnership
-Data and Intellectual Property Protections for Pharmaceuticals
-Regulatory Transparency
Transatlantic Trade and Investment Partnership
-Ag-Biotech Issues
-Intellectual Property Issues
-Regulatory Harmonization
-Reimbursement Transparency
Biosimilars
-Mexico Biologics Regulations
-Colombia Biologics Regulations
Trade Promotion Authority
Colombia National Development Plan
-Regulatory Issues
-Reimbursement Issues
-Intellectual Property Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Cathleen |
Enright |
|
|
|
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Derrick |
White |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Hans |
Sauer |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |